Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity.

AIMS Methadone is characterized by wide intersubject variability regarding the dose needed to obtain full therapeutic response. We assessed the influence of sociodemographic, ethnic, clinical, metabolic and genotypic variables on methadone maintenance dose requirement in opioid-dependent responder patients. METHODS Eighty-one stable patients (60 men and 21 women, 43.7 ± 8.1 years old, 63.1 ± 50.9 mg day(-1) methadone), divided into quartiles with respect to the median daily dose, were enrolled and underwent clinical examination, treatment history and determination of liver/intestinal cytochrome P450 (CYP) 3A4 activity measured by the midazolam test, R,S-methadone trough concentration and clinically significant polymorphisms of the OPRM1, DRD2, COMT, ABCB1, CYP2B6, CYP3A5, CYP2C19 and CYP2D6 genes. RESULTS Methadone maintenance dose was correlated to the highest dose ever used (r(2) = 0.57, P < 0.0001). Fractioned methadone intake (odds ratio 4.87, 95% confidence interval 1.27-18.6, P = 0.02), bodyweight (odds ratio 1.57, 95% confidence interval 1.01-2.44, P = 0.04), history of cocaine dependence (80 vs. 44 mg day(-1) in never-addict patients, P = 0.005) and ethnicity (Asian > Caucasian > African, P = 0.04) were independently associated with high-dose methadone in multiple regression analysis. A modest correlation was observed between liver/intestinal CYP3A4 activity and methadone dose at steady state (Spearman rank correlation coefficient [rs ] = 0.21, P = 0.06) but not with highest dose ever used (rs = 0.15, P = 0.18) or dose-normalized R,S-methadone trough concentrations (rs = -0.05, P = 0.64). Concomitant CYP3A4 inhibitors only affected the relationship between methadone dose and R,S-methadone trough concentration. None of the genetic polymorphisms explored was predictive of the methadone maintenance dose. CONCLUSIONS Methadone maintenance dose was predicted by sociodemographic and clinical variables rather than genetic polymorphisms or liver/intestinal CYP3A4 activity in stable patients.

[1]  H. Pollack,et al.  Evidence-based treatment for opioid disorders: a 23-year national study of methadone dose levels. , 2014, Journal of substance abuse treatment.

[2]  D. Greenblatt.  Drug interactions with methadone: Time to revise the product label , 2014, Clinical pharmacology in drug development.

[3]  E. Kharasch,et al.  Cytochrome P4503A Does Not Mediate the Interaction between Methadone and Ritonavir-Lopinavir , 2013, Drug Metabolism and Disposition.

[4]  O. Levran,et al.  CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction , 2013, Addiction biology.

[5]  E. Kharasch,et al.  Role of Cytochrome P4502B6 in Methadone Metabolism and Clearance , 2013, Journal of clinical pharmacology.

[6]  G. Tucker,et al.  Pharmacokinetic-Pharmacodynamic Modeling of Mood and Withdrawal Symptoms in Relation to Plasma Concentrations of Methadone in Patients Undergoing Methadone Maintenance Treatment , 2012, Journal of clinical psychopharmacology.

[7]  E. Cuyás,et al.  Contribution of Cytochrome P450 and ABCB1 Genetic Variability on Methadone Pharmacokinetics, Dose Requirements, and Response , 2011, PloS one.

[8]  J. Svärd,et al.  Nuclear Receptor-Mediated Induction of CYP450 by Antiretrovirals: Functional Consequences of NR1I2 (PXR) Polymorphisms and Differential Prevalence in Whites and Sub-Saharan Africans , 2010, Journal of acquired immune deficiency syndromes.

[9]  M. Kreek,et al.  Pharmacotherapy in the Treatment of Addiction: Methadone , 2010, Journal of addictive diseases.

[10]  M. Preisig,et al.  Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[11]  J. Ott,et al.  ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. , 2008, Human molecular genetics.

[12]  K. Bain,et al.  Actual and potential drug interactions associated with methadone. , 2008, Pain medicine.

[13]  T. Kosten,et al.  Pharmacogenetic Treatments for Drug Addiction: Alcohol and Opiates , 2008, The American journal of drug and alcohol abuse.

[14]  C. Eap,et al.  In vitro P-Glycoprotein-Mediated Transport of (R)-, (S)-, (R,S)-Methadone, LAAM and Their Main Metabolites , 2007, Pharmacology.

[15]  C. Eap,et al.  Could pharmacogenetic data explain part of the interindividual sensitivity to methadone-induced respiratory depression? , 2007, Critical care.

[16]  X. Laqueille,et al.  Méthadone : de la pharmacocinétique à la pharmacologie clinique , 2006 .

[17]  J. Lötsch,et al.  Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action , 2006, Clinical pharmacology and therapeutics.

[18]  C. Eap,et al.  Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment , 2005, Clinical pharmacology and therapeutics.

[19]  A. Bertolini,et al.  Methadone--metabolism, pharmacokinetics and interactions. , 2004, Pharmacological research.

[20]  E. Kharasch,et al.  Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone , 2004, Clinical pharmacology and therapeutics.

[21]  E. Kharasch,et al.  The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. , 2004, British journal of clinical pharmacology.

[22]  Thierry Buclin,et al.  Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance , 2004, Clinical pharmacology and therapeutics.

[23]  J. Donovan,et al.  Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood–brain barrier of Abcb1a gene knockout mice , 2004, Psychopharmacology.

[24]  P. Jatlow,et al.  The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  C. Eap,et al.  Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. , 2003, Drug and alcohol dependence.

[26]  C. Eap,et al.  Paroxetine Increases Steady-State Concentrations of (R)-Methadone in CYP2D6 Extensive but Not Poor Metabolizers , 2002, Journal of clinical psychopharmacology.

[27]  P. Watkins,et al.  In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. , 2001, Pharmacogenetics.

[28]  P. Arnaud,et al.  Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate , 2001, Clinical pharmacology and therapeutics.

[29]  D. Greenblatt,et al.  Methadone inhibits rhodamine123 transport in Caco-2 cells. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[30]  METHADONE INHIBITS RHODAMINE 123 TRANSPORT IN CACO-2 CELLS , 2001 .

[31]  J. Spagnoli,et al.  Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. , 2000, Drug and alcohol dependence.

[32]  C. Bernards,et al.  Opiate-induced Analgesia Is Increased and Prolonged in Mice Lacking P-glycoprotein , 2000, Anesthesiology.